CRISPR Therapeutics AG (CRSP)

NASDAQ: CRSP · IEX Real-Time Price · USD
61.79
-1.78 (-2.79%)
At close: Jun 17, 2024, 4:00 PM
62.21
+0.43 (0.69%)
Pre-market: Jun 18, 2024, 8:32 AM EDT
-2.79%
Market Cap 5.25B
Revenue (ttm) 271.71M
Net Income (ttm) -217.14M
Shares Out 84.92M
EPS (ttm) -2.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,219,039
Open 62.85
Previous Close 63.56
Day's Range 61.14 - 62.89
52-Week Range 37.55 - 91.10
Beta 1.78
Analysts Buy
Price Target 80.29 (+29.95%)
Earnings Date Aug 5, 2024

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product cand... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 19, 2016
Employees 407
Stock Exchange NASDAQ
Ticker Symbol CRSP
Full Company Profile

Financial Performance

In 2023, CRSP's revenue was $371.21 million, an increase of 30885.48% compared to the previous year's $1.20 million. Losses were -$153.61 million, -76.37% less than in 2022.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is $80.29, which is an increase of 29.95% from the latest price.

Price Target
$80.29
(29.95% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseas...

20 days ago - GlobeNewsWire

Final Trade: UAL, NKE, SLV & CRSP

The final trades of the day with CNBC's Melissa Lee and the Option Action traders.

Other symbols: SLVNKEUAL
24 days ago - CNBC Television

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A.

26 days ago - GlobeNewsWire

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseas...

5 weeks ago - GlobeNewsWire

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

-More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected-

5 weeks ago - GlobeNewsWire

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma -

5 weeks ago - GlobeNewsWire

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...

2 months ago - GlobeNewsWire

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...

2 months ago - GlobeNewsWire

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...

2 months ago - GlobeNewsWire

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

ZUG, Switzerland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...

3 months ago - GlobeNewsWire

Final Trade: HPQ, RSG, GM, CRSP

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: GMHPQRSG
3 months ago - CNBC Television

Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed

Samarth Kulkarni, Crispr Therapeutics CEO, joins 'Power Lunch' to discuss the hurdles to getting rare disease drugs through regulation, what consumers can look forward to in gene editing, and much mor...

3 months ago - CNBC Television

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain —

4 months ago - GlobeNewsWire

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...

4 months ago - GlobeNewsWire

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and diabete...

4 months ago - GlobeNewsWire

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

— Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment —

4 months ago - GlobeNewsWire

FDA Approves New CRISPR Gene-Editing Treatment

The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusio...

Other symbols: VRTX
5 months ago - Forbes

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment- ZUG, Switzerland and BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (N...

5 months ago - GlobeNewsWire

US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder

The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a rare blood disorder requiring regular blood transfusions, in patients 1...

Other symbols: VRTX
5 months ago - Reuters

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...

5 months ago - GlobeNewsWire

CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...

5 months ago - GlobeNewsWire

Crispr Therapeutics chief medical officer is resigning

Crispr Therapeutics CRSP, +8.84% on Tuesday said that Phuong Khanh Morrow was resigning as the gene-editing company's chief medical officer, a move that takes hold on Jan. 26. The resignation was “not...

6 months ago - Market Watch

Final Trades: PBR, DELL, FSLR & CRSP

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: DELLFSLRPBR
6 months ago - CNBC Television

CRISPR Therapeutics CEO talks winning FDA approval for sickle cell anemia treatment

Samarth Kulkarni, CRISPR Therapeutics CEO, joins 'Closing Bell Overtime' to talk winning FDA approval in the U.S. for sickle cell treatment in partnership with Vertex.

6 months ago - CNBC Television

Sickle cell gene editing faces market hurdles: Analyst

"The FDA approved a gene editing treatment for sickle cell disease to alleviate severe, recurrent pain crises. Casgevy, developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), is a ...

Other symbols: VRTX
6 months ago - Yahoo Finance